Importantly, we show that JAK2–STAT3/TrkA pathway co-activation is a new prognostic indicator of distant metastasis to various organs, prompting a future study to examine combined inhibition of JAK2–STAT3 and TrkA pathways as a novel and viable combination therapy in metastatic triple-negative and HER2-enriched breast cancers. Here, ERBB2 is linked to breast cancer.